Hefei, China, October 21, 2024 -- Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company was invited to participate in the upcoming 7th Annual TPD (Targeted Protein Degradation) & Induced Proximity Summit, to be held in Boston, MA, October 28-31, 2024. Yao Wang, Chief Medical Officer, will deliver an oral presentation and introduce the company’s leading technology in the area of TPD.
Presentation Title: Unearthing Clinical Findings from the Degrader KPG-121 in mCRPC
TRACK C: TRANSLATIONAL/CLINICAL, Safety, Toxicology, & Clinical Efficacy of Degraders Progressing Through Clinic
Time: 11:30 AM, October 30, 2024 (Eastern Time)
Yao will also be the chair moderator of TRACK C: TRANSLATIONAL/CLINICAL on October 29, 1:30 to 5:00 PM, to discuss the latest progress of TPD with renowned experts from around the world.
More information about the 7th Annual TPD & Induced Proximity Summit is available on the website https://proteindegradation.com
About Kangpu Biopharmaceuticals
Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative molecular glue-based therapeutics for the treatment of autoimmune diseases, solid tumors, hematologic malignancies and inflammatory disorders. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES®, gDACS®, and X-SYNERGY®.